Jefferies Raises Price Target on BioMarin Pharma (BMRN) to $120; Reiterates Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Jefferies Raises Price Target on BioMarin Pharma (BMRN) to $120; Reiterates Buy

BioMarin Announces Second Quarter 2016 Financial Results

August 4, 2016 4:03 PM EDT

- Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million

- Vimizim Net Product Revenue Increases 98.1% Y/Y and Contributes $106.8 million in the Second Quarter 2016; Vimizim Full-year Revenue Guidance Increased to $340 to $360 million

- Kuvan Net Product Revenue Contributes $90.2 million in the Second Quarter 2016; Kuvan Full-year Revenue Guidance Increased to $340 to $360 million

- Strong Kuvan and Vimizim Results Drive Increased FY 2016 Top-line Guidance to $1.10 billion - $1.15 billion

Financial Highlights (in millions of U.S. dollars, except per share data,... More